Observational study of pimecrolimus 1% cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of life

• Egile Nagusiak: Nikolay N. Murashkin (Egilea), Leyla S. Namazova-Baranova (Egilea), Svetlana G. Makarova (Egilea), Roman A. Ivanov (Egilea), Stepan G. Grigorev (Egilea), Dmitri V. Fedorov (Egilea), Eduard T. Ambarchian (Egilea), Roman V. Epishev (Egilea), Alexander I. Materikin (Egilea), Leonid A. Opryatin (Egilea), Alena A. Savelova (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

IntroductionEpidermal barrier dysfunction in children with atopic dermatitis can cause transcutaneous sensitization to allergens and allergic diseases. We evaluated the effectiveness of an early-intervention algorithm for atopic dermatitis treatment, utilizing pimecrolimus for long-term maintenance...